Un nou estudi del grup del doctor Manel Esteller, director del Programa d’Epigen\u00e8tica i Biologia del C\u00e0ncer (PEBC) de l’Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Investigador ICREA i catedr\u00e0tic de Gen\u00e8tica de la Universitat de Barcelona, \u200b\u200bpresenta un f\u00e0rmac epigen\u00e8tic capa\u00e7 de frenar el creixement de les c\u00e8l\u00b7lules de limfoma de les c\u00e8l\u00b7lules del mantell (MCL), un c\u00e0ncer caracteritzat pel seu comportament agressiu, el seu diagn\u00f2stic tard\u00e0 amb afectaci\u00f3 de diferents \u00f2rgans i el seu origen a partir dels limf\u00f2cits B. Els resultats de la recerca, publicats a la revista Haematologica, l’\u00f2rgan d’expressi\u00f3 de la Societat Europa d’Hematologia (EHA), responen a la necessitat m\u00e8dica de descobrir nous medicaments per incrementar la superviv\u00e8ncia a llarg termini en aquesta malaltia.<\/p>\n
\u00a0<\/p>\n
“El nostre laboratori est\u00e0 interessat en trobar nous compostos amb activitat epigen\u00e8tica i efecte antitumoral. Col\u00b7laborant amb qu\u00edmics org\u00e0nics i l’empresa Quimatryx vam obtenir una mol\u00e8cula que actua inhibint el gen HDAC6, una prote\u00efna que modifica qu\u00edmicament altra prote\u00efnes mitjan\u00e7ant l’acetilaci\u00f3.” comenta el Manel Esteller, autor principal de l’estudi. La investigaci\u00f3 tamb\u00e9 s’ha realitzat amb la col\u00b7laboraci\u00f3 cl\u00ednica dels Serveis d’Hematologia de l’Institut Catal\u00e0 d’Oncologia (ICO) a l’Hospitalet i Badalona, \u200b\u200baix\u00ed com de l’Institut Josep Carreras (IJC).<\/p>\n
\u00a0<\/p>\n
“Estudiant diversos tipus de c\u00e0ncer, ens vam adonar que l’efic\u00e0cia de la nova mol\u00e8cula era m\u00e0xima per a aquest tipus de limfoma. Aquest efecte benefici\u00f3s es va observar en c\u00e8l\u00b7lules cultivades, estudis murins i c\u00e8l\u00b7lules extretes de pacients. A m\u00e9s, la subst\u00e0ncia \u00e9s molt espec\u00edfica pel que fa a la seva diana d’acci\u00f3, amb aparent poca toxicitat per a c\u00e8l\u00b7lules sanes del mateix pacient, com serien els limf\u00f2cits de tipus T”, afegeix l’investigador de l’IDIBELL sobre la recerca a Haematologica.<\/p>\n
\u00a0<\/p>\n
Un 12% del c\u00e0ncer en la poblaci\u00f3 mundial es deriva de de les c\u00e8l\u00b7lules de la sang, ja sigui una leuc\u00e8mia, un limfoma o un mieloma, diagnosticant un pacient nou cada dos minuts. Encara que alguns d’aquests processos oncol\u00f2gics hematol\u00f2gics s\u00f3n curables, per a d\u2019altres no existeixen tractaments prou efica\u00e7os. “El que ens alegra especialment en aquest cas \u00e9s que es comenci a plantejar el possible \u00fas del f\u00e0rmac en assaigs cl\u00ednics per al proper any”, conclou Esteller.<\/p>\n","protected":false},"excerpt":{"rendered":"
Un nou estudi del grup del doctor Manel Esteller, director del Programa d’Epigen\u00e8tica i Biologia del C\u00e0ncer (PEBC) de l’Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Investigador ICREA i catedr\u00e0tic de Gen\u00e8tica de la Universitat de Barcelona, \u200b\u200bpresenta un f\u00e0rmac epigen\u00e8tic capa\u00e7 de frenar el creixement de les c\u00e8l\u00b7lules de limfoma de les c\u00e8l\u00b7lules del mantell […]<\/p>\n","protected":false},"author":6,"featured_media":10574,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,376],"tags":[],"class_list":["post-7631","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-epigenetica-del-cancer"],"publishpress_future_action":{"enabled":false,"date":"2024-11-29 16:48:09","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7631"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7631\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/10574"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}